Allorion Therapeutics

United States - Natick, Massachusetts

• 13/03/2023
• Series B
• $50,000,000

At Allorion Therapeutics, we focus on developing novel small molecule drugs against cancer and autoimmune diseases. Our team is comprised of experts in cancer biology and drug development. The fields we want to dive into include:

• selecting well-validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of actions
• building our innovative data and screening platforms for sustainable success
• constructing chemical libraries with priorities on allosteric and covalent modulators and optimizing the libraries through the aid of AI

Allorion has dual sites operating in Natick, Massachusetts and Guangzhou, China.

Related People

Fang LiCo Founder

United States - Cambridge, Massachusetts,

I am a research professional working in the pharmaceutical industry. I have extensive oncology and immuno-oncology experience from target ID/validation, lead discovery and optimization to translational research and early-phase clinical trials.

I lead cross-functional teams with diverse expertise, ranging from cancer biology and computational biology to clinical assay development. I am skilled at building collaborations with CROs and investigators in academia resulting in clinical trials and high impact publications.

LinkedIn https://www.linkedin.com/in/fang-li-919a3739/